FDA Expects 25 Formal Dispute Resolution Requests Annually On GMP Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency has not changed its projection that the number of annual requests for formal dispute resolution will reach 25, almost double the current number of informal disputes, despite the results of a year-long pilot program that had little industry participation.
You may also be interested in...
FDA Moving Toward PAT Standardized Nomenclature And Definitions
The process analytical technology component of FDA's drug quality initiative will be assisted by an independent standards-making effort and agency encouragement of comparability protocols. Part 11 and dispute resolution are other quality initiative components drawing industry input.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.